Aquestive Therapeutics (AQST) Revenue (2017 - 2026)
Aquestive Therapeutics (AQST) revenue from Jun 30, 2017 to Mar 31, 2026. The TTM Aquestive Therapeutics (AQST) revenue is $50M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Aquestive Therapeutics (AQST) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -7.28% |
| 3 Years TTM | +2.61% |
| 5 Years TTM | +0.84% |
| All Time TTM | -3.16% |
Annual Revenue change of Aquestive Therapeutics (AQST)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $14M | -67.56% |
| 2025 | $45M | -22.60% |
| 2024 | $58M | +13.80% |
| 2023 | $51M | +6.08% |
| 2022 | $48M | -6.20% |
| 2021 | $51M | +10.86% |
| 2020 | $46M | -12.85% |
| 2019 | $53M | -21.98% |
| 2018 | $67M | +0.76% |
| 2017 | $67M | N/A |
Comparison Aquestive Therapeutics (AQST) five years revenue CAGR with competitors
Aquestive Therapeutics (AQST) five years revenue CAGR is 0.84%.